Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

434.40DKK
25 May 2018
Change (% chg)

kr.6.00 (+1.40%)
Prev Close
kr.428.40
Open
kr.429.50
Day's High
kr.434.50
Day's Low
kr.429.50
Volume
438,224
Avg. Vol
407,104
52-wk High
kr.434.50
52-wk Low
kr.280.80

Chart for

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.97
Market Cap(Mil.): kr.86,470.13
Shares Outstanding(Mil.): 199.06
Dividend: 8.00
Yield (%): 1.84

Financials

  LUN.CO Industry Sector
P/E (TTM): 26.62 29.19 33.30
EPS (TTM): 16.32 -- --
ROI: 25.58 13.53 13.04
ROE: 30.17 15.25 14.90

BRIEF-H Lundbeck says FDA updates Trintellix label to include data showing improvement in processing speed

* REG-FDA UPDATES TRINTELLIX® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD)

May 02 2018

BRIEF-Lundbeck Says New CEO To Be Named Within Six Months

* INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS

Feb 07 2018

UPDATE 1-Lundbeck's Q4 operating profit falls short of expectations

COPENHAGEN, Feb 7 Danish drugmaker Lundbeck posted weaker than expected fourth quarter operating profit and gave a broad range for its 2018 financial guidance because of a range of uncertainties.

Feb 07 2018

Lundbeck's Q4 operating profit below expectations

COPENHAGEN, Feb 7 Drugmaker Lundbeck's fourth-quarter operating profit came in at 932 million Danish crowns ($155.19 million), undershooting the 1.05 billion expected by analysts in a Reuters poll.

Feb 07 2018

BRIEF-H Lundbeck Enters Research Partnership On Treatment Of Schizophrenia

* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA

Jan 05 2018

BRIEF-Lundbeck: Brintellix Approved In China

* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 04 2017

Earnings vs. Estimates